New UCLA Health Study Reveals Promising Early Evidence That Oxaloacetate Supplement May Relieve Post-Treatment Brain Fog in Breast Cancer Survivors

For millions of individuals who successfully navigate the physical and emotional turbulence of cancer diagnoses, the conclusion of medical treatment does not always signal an immediate return to normalcy. While the eradication of malignant cells represents a monumental victory, many survivors find themselves grappling with an invisible and persistent aftermath. Among the most frustrating of these lingering symptoms is a constellation of cognitive hurdles frequently referred to by patients and clinicians alike as chemo brain or brain fog. Marked by frustrating memory lapses, debilitating difficulties with concentration, and a profound, persistent exhaustion that sleep cannot cure, these post-treatment side effects can severely compromise a survivor’s professional productivity, social engagement, and overall quality of life.

Addressing this critical unmet need in oncology, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have recently uncovered promising early evidence suggesting that a naturally occurring molecular supplement could offer substantial relief. In a pioneering phase II clinical trial, breast cancer survivors who incorporated an oxaloacetate-based supplement into their daily routines for an eight-week period reported noticeable, statistically significant improvements in their cognitive function, memory retention, attention spans, and energy levels. While the medical community remains cautiously optimistic—underscoring the absolute necessity for larger, randomized trials—these preliminary findings illuminate a potential therapeutic pathway for a condition that has historically eluded effective clinical management.

The details of this investigation, published in the peer-reviewed journal JCO Oncology Advances, highlight not only subjective improvements perceived by the patients themselves but also measurable gains on standardized cognitive assessments. Specifically, participants demonstrated enhanced processing speed and superior executive functioning—the complex mental processes required for planning, multi-tasking, maintaining focus, and mental flexibility. As oncologists and researchers continue to seek ways to maximize the long-term well-being of the growing population of cancer survivors, this novel intervention offers a compelling glimpse into the future of supportive oncology care.

Understanding the Complex Etiology of Cancer-Related Cognitive Impairment

To fully grasp the significance of the UCLA research, one must examine the pervasive and debilitating nature of cancer-related cognitive impairment (CRCI). Epidemiological and clinical data indicate that roughly 15% to 25% of all breast cancer survivors experience ongoing, long-term difficulties with memory, concentration, and cognitive processing speed long after their active treatments have concluded. These challenges can manifest immediately following therapy or emerge months later, persisting for years and creating profound barriers in both personal and professional spheres.

Historically, the medical community attributed these cognitive deficits primarily to chemotherapy, hence the colloquial and widely recognized term chemo brain. However, modern oncological science recognizes that the etiology of CRCI is far more complex and multifaceted. Contemporary research demonstrates that cognitive decline in cancer survivors is rarely the result of a single factor. Instead, it typically stems from a constellation of overlapping biological processes. These include the direct neurotoxic effects of systemic chemotherapeutic agents, the endocrine manipulation of hormone-suppressive therapies, chronic systemic inflammation triggered by the cancer and its treatments, hormonal fluctuations, and various behavioral and psychological influences, such as anxiety, depression, and sleep disruption.

Because the underlying physiological mechanisms driving brain fog are so intricate, effective treatments have remained frustratingly elusive. Traditional pharmacological interventions—such as psychostimulants typically prescribed for attention deficit hyperactivity disorder or wakefulness-promoting agents used for narcolepsy—have yielded mixed results in cancer populations and frequently carry undesirable side effects profile, including cardiovascular strain, anxiety, and insomnia. Consequently, researchers have shifted their focus toward addressing the root biological disruptions that compromise normal neuronal communication and cellular energy metabolism within the central nervous system.

At the intersection of inflammation, brain chemistry, and cellular energetics lies a compelling area of scientific inquiry. Chronic inflammation resulting from oncological treatments can severely interfere with glutamate signaling—a critical neurotransmitter system responsible for facilitating communication between nerve cells. Furthermore, this inflammatory state can disrupt the metabolic pathways that allow brain cells, or neurons, to efficiently produce and utilize energy in the form of adenosine triphosphate (ATP). When neuronal energy production falters and neurotransmitter signaling is disrupted, the inevitable clinical manifestations are mental exhaustion, delayed processing speeds, and cognitive failure.

The Biological Mechanism and Rationale of Oxaloacetate

It was within this context of cellular bioenergetics and neuroinflammation that oxaloacetate first captured the attention of the research team at UCLA Health. Oxaloacetate is a naturally occurring four-carbon dicarboxylic acid that plays a fundamental role in aerobic cellular respiration, specifically serving as a key intermediate in the Krebs cycle (also known as the citric acid cycle or TCA cycle), which is the primary mechanism by which cells generate chemical energy.

Beyond its foundational role in mitochondrial energy production, oxaloacetate possesses unique neuroprotective and metabolic properties. Preclinical and biochemical studies have demonstrated that oxaloacetate acts as a potent scavenger of reactive oxygen species and can modulate glutamate levels in the extracellular space. By regulating glutamate availability, oxaloacetate helps prevent excitotoxicity—a pathological process wherein excessive glutamate over-stimulates neurons, leading to cellular damage or death. Additionally, by supporting mitochondrial function and enhancing cellular energy metabolism, oxaloacetate addresses two of the primary suspected drivers of cancer-related cognitive impairment: energy deficits within neurons and inflammation-mediated signaling disruptions.

Motivated by these biochemical attributes, the UCLA investigators hypothesized that administering supplemental oxaloacetate could ameliorate the debilitating cognitive symptoms and persistent fatigue reported by breast cancer survivors. To test this hypothesis, the research team designed a focused, phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the supplement in a real-world patient cohort.

Methodology and Chronology of the UCLA Phase II Clinical Trial

The clinical investigation enrolled 18 female participants who had been diagnosed with early-stage breast cancer between one and five years prior to the study’s commencement. All individuals entering the trial reported substantial, ongoing cognitive difficulties and persistent fatigue that negatively impacted their daily functioning. The average age of the participants was approximately 50 years, representing a critical demographic of working-age women managing both professional responsibilities and familial duties while attempting to navigate survivorship.

Reflecting standard treatment pathways for early-stage breast cancer, the vast majority of the study participants had previously undergone systemic chemotherapy. Furthermore, nearly 90% of the cohort were actively receiving ongoing endocrine therapy—such as aromatase inhibitors or tamoxifen—at the time of the trial, medications notoriously associated with joint pain, fatigue, and cognitive slowing.

The protocol required each participant to ingest a 500-milligram capsule of oxaloacetate twice daily for a continuous duration of eight weeks. To rigorously track outcomes, the research team utilized a multi-faceted evaluation framework combining subjective patient-reported metrics with objective, standardized neuropsychological testing. Participants completed comprehensive questionnaires designed to quantify perceived cognitive impairment, fatigue levels, sleep quality, psychological distress (including anxiety and depression), and overall physical and mental well-being. Concurrently, objective cognitive tests were administered to measure specific domains of brain function, including processing speed, sustained attention, working memory, and executive function. Safety and tolerability were closely monitored throughout the eight-week treatment window to record any potential adverse events.

Significant Clinical Improvements Observed After Eight Weeks

Of the 18 women who initially enrolled in the clinical trial, 16 successfully completed the full eight-week supplementation protocol. The results gathered from this cohort provided striking, encouraging preliminary evidence of the supplement’s potential benefits. Every single participant who completed the study reported a marked, significant improvement in her subjective cognitive symptoms.

The most dramatic changes were documented in the study’s primary endpoint: perceived cognitive impairment scores. Prior to initiating the oxaloacetate regimen, the participants recorded an average impairment score of 29.1, reflecting severe, lifestyle-disrupting brain fog. Following eight weeks of twice-daily supplementation, the group’s average score surged to 55.5. This substantial upward shift effectively moved the cohort out of the clinical range for cognitive impairment and into the normal range of functioning.

Notably, the timeline of recovery demonstrated early traction. Indications of cognitive enhancement were detectable as early as four weeks into the trial, with the magnitude of reported benefits generally amplifying as the eight-week intervention progressed.

The positive effects extended well beyond subjective memory and concentration. Participants reported statistically significant reductions in general fatigue and mental exhaustion, which historically hinder their ability to engage in routine daily activities. Concurrently, survivors noted meaningful enhancements in their overall physical health and functional capacity. These subjective accounts were further corroborated by standardized cognitive testing, which revealed measurable improvements in processing speed and executive function, aligning objective performance gains with the participants’ personal experiences of recovery.

Safety Profile and Tolerability

In evaluating any novel therapeutic intervention for cancer survivors, safety and tolerability are paramount considerations. During the eight-week study, oxaloacetate was generally well tolerated by the participants, though adverse events were noted. The most frequently reported side effects were confined to the gastrointestinal tract, including mild to moderate indigestion, abdominal bloating, constipation, diarrhea, and nausea.

These digestive complaints led two of the enrolled women to discontinue their participation in the trial prematurely. However, no serious adverse events were recorded among the participants who completed the study, indicating a favorable safety profile relative to many conventional pharmaceutical agents used to manage neurological symptoms.

Expert Perspectives and the Need for Rigorous Follow-Up Studies

Despite the enthusiasm generated by these preliminary outcomes, the study’s authors and leading oncologists have strongly emphasized the need for caution. Because the phase II trial was relatively small and lacked a placebo control group or randomization schema, researchers cannot definitively prove at this stage that oxaloacetate was the direct and sole catalyst for the observed improvements. In clinical research, the absence of a control group leaves open the possibility of a placebo effect or natural recovery over time, making rigorous scientific validation essential before broad clinical recommendations can be made.

Dr. Patricia Ganz, distinguished professor of medicine at the David Geffen School of Medicine at UCLA and the UCLA Fielding School of Public Health, as well as the study’s first author, underscored both the gravity of the problem and the promise of the research. "Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it," Dr. Ganz stated. Addressing the trial’s findings, she added, "These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment."

The Broader Implications and Future Research Roadmap

Building directly upon the foundational insights gained from this initial trial, the research team at UCLA Health has already initiated steps toward the next phase of scientific validation. The investigators have been actively organizing a comprehensive, randomized, placebo-controlled phase II clinical trial specifically designed to enroll a larger cohort of breast cancer survivors suffering from cancer-related cognitive impairment. Enrollment for this advanced study was slated to begin in late 2026.

By implementing a randomized, double-blind, placebo-controlled design, the research team aims to eliminate confounding variables and definitively determine whether oxaloacetate produces statistically significant, measurable cognitive and physical benefits that far exceed any placebo response. This gold-standard methodological approach will provide the definitive evidence required by the broader oncological community.

Simultaneously, the investigators are conducting vital preclinical research utilizing animal models to elucidate the exact neurobiological mechanisms through which oxaloacetate influences the central nervous system and metabolic pathways. These ongoing laboratory experiments include parallel placebo-controlled animal studies designed to verify whether the molecule elicits similar improvements in physical function and fatigue reduction in vivo.

This extensive research endeavor has received critical financial backing from prominent philanthropic and federal institutions, including partial support from the Breast Cancer Research Foundation and the National Cancer Institute. The multidisciplinary research team behind the study features a distinguished roster of UCLA experts, including Dr. Kathleen Van Dyk, Dr. Catherine M. Crespi, Laura Petersen, Dr. Mina Sedrak, and Dr. Julienne Bower, reflecting a collaborative institutional commitment to improving survivorship care.

As the scientific community awaits the results of the upcoming larger clinical trials, the initial findings regarding oxaloacetate offer a beacon of hope for countless breast cancer survivors. By targeting the fundamental cellular and metabolic disruptions that underlie chemo brain and persistent fatigue, this line of research points toward a future where conquering cancer does not demand a permanent compromise in cognitive vitality and quality of life.